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Abstract Phospholipase A2 (PLA2) from human pancreas, des- 
ignated hPLAz-I, functions as a digestive enzyme. Interestingly, 
the present study demonstrated that the mature form of hPLA2-I 
stimulated the growth of a human pancreatic cancer cell line 
MIAPaCa-2, whereas the pro-form was ineffective. PLA2s from 
Laticauda semifasciata fraction I, Crotalus adamanteus venom, 
Streptomyces violaceoruber and bee venom, showed no prolifera- 
tive effect to the growth of MIAPaCa-2. The Scatchard plot 
analysis revealed that the MIAPaCa-2 cell had a specific binding 
site for the mature hPLA2-I. The equilibrium binding constant 
(Kd) and the maximum binding capacity (Bmax) were 2.6 nM and 
0.4 fmol/10 6 cells, respectively. These results suggest that the 
mature hPLA2-I, but not the pro-form, may function as a growth 
factor of pancreas carcinoma via the specific binding site. 
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functions have been suspected: it has been suggested that a 
receptor for PLA 2 is present on the surface of mammalian cells, 
as a result of the binding assay of the porcine PLA 2 to some 
mammalian cells except porcine [8 10]. Cobra venom PLA2 
also belongs to group I [6]. PLA2 isolated from human rheuma- 
toid arthritic synovial fluid, which belongs to group II together 
with PLA2 from Crotalus adamanteus venom [11], has been 
reported to play an important role in inflammation. PLA 2 from 
bee venom, included in group III, plays a role in bee sting 
inflammation [11 14]. A new type of 14-kDa PLA2 has been 
recently isolated from a filamentous bacteria Streptomyces vi- 
olaceoruber [15]. 
The present study shows that hPLA2-I, acting as a digestive 
enzyme, stimulates the growth of human pancreatic ancer cell 
line via specific binding to the PLA 2 receptor. 
2. Materials and methods 
1. Introduction 
The incidence of pancreatic arcinoma in Japan has risen 
sharply from 1.8 to 5.2 per 100,000 people during 1960 1985 
[1]. In the United States, the ranking of the same carcinoma is 
the fourth of fifth leading cause of cancer death with an overall 
1-year survival of only 12%. Judging from our observation that 
the outlook for patients after the diagnosis of pancreatic arci- 
noma has been poor, it is suggested that there are some mech- 
anisms which play important roles in dramatically promoting 
the growth of pancreas carcinoma [2]. Gastrin, cholecystokinin, 
and epidermal growth factor, in fact, have recently been re- 
ported to stimulate the proliferation of pancreatic adeno- 
carcinoma cells in tissue culture [3,4]. 
Phosphol ipase A 2 (PLA2) catalyzes the hydrolysis of the fatty 
acid at the sn-2 position in phospholipids to liberate free acids 
and lysophospholipids [5]. PLA2s have been isolated from sev- 
eral mammalian sources as intracellular or extracellular en- 
zymes [6]. The extracellular 14-kDA PLA2s have been classified 
into three groups, according to characteristics in their primary 
structures [6]. The enzyme, included into group I, exists in the 
pancreatic juice, kidney, small intestine, stomach, and lung 
from various animal specimens [7]. In those organs, not only 
the function of PLA2-I as a digestive nzyme but also any other 
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Abbreviations: h, human; PLA2, phospholipase A2; PAGE, poly- 
acrylamide gel electrophoresis; SDS, sodium dodecyl sulphate. 
2.1. Sources of PLA 2 and the cancer cell line 
The hPLA2-I was purified from pancreatic juice by modifying the 
method described previously [16]. The purified hPLA2-I was electro- 
phoretically transferred to a nitrocellulose membrane (Schleicher and 
Schuell, Germany) and detected immunologically using an anti-human 
PLA2 mouse monoclonal ntibody (Boehringer-Mannheim, Germany). 
The amino acid sequence ofhPLAz-I was determined by Edman degra- 
dation method using an autosequencer (PSQ-2, Shimadzu, Japan). 
Iodination of the mature hPLA2-I was carried out by the methods using 
chloramine-T [17]. The specific activity of 125I-labelled hPLA2-I was 
about 2500 cpm/fmol. PLA2s from Crotalus adamanteus venom (group 
II, product no. 790 in Sigma catalogue-) and bee venom ofApis mellifera 
(group III, product no. 1264 in Sigma catalogue) were purchased from 
Sigma Chemical Co., Ltd. The microbial PLA2, produced extracellulary 
by Streptomyces violaceoruber, was a kind gift from Asahi Chemical 
Industry Co., Ltd., Japan. PLA 2 from Laticauda semifasciata fraction 
I (group I) was a generous gift from Dr. C. Takasaki (Tohoku Univer- 
sity, Japan) and Dr. K. Teshima (Hiroshima University, Japan). The 
pro-form of hPLA2-I was a generous gift from Shionogi Pharmaceuti- 
cals Co., Ltd., Japan. MIAPaCa-2 was supplied by Japanese Cancer 
Research Resources Bank. MIAPaCa-2 cell line was grown in Dul- 
becco's modified Eagle's medium (D-MEM) with 10% foetal bovine 
serum (Gibco, USA) in humidified atmosphere of5% CO2 and 95% air 
at 37°C. 
2.2. Cell proliferation assay 
The cell proliferation was assayed by two methods. Method A is a 
method which assays the growth of cells by measuring the absorbance 
at 450 nm. The MIAPaCa-2 (2.5 x 104) were plated into 0.6 cm 2 in 
96-well plates, in D-MEM containing 10% foetal bovine serum (FBS). 
After incubation for 24 h, the medium was removed, and then the same 
medium containing 0.1% FBS was added to each well. The cells were 
grown for 24 or 48 h in D-MEM containing 0.1% FBS medium, or the 
same medium containing PLA2s from human, bee venom, Streptomyces 
violaceoruber, Crotalus adamanteus venom, and Laticauda semifasciata 
fraction I at the given concentrations (10, 25 and 50 nM), respectively. 
The cells were grown in humidified atmosphere of5% CO2 and 95% air 
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at 37°C. After incubation for 24 h or 48 h, the cell proliferation assay 
was carried out using a sulphonated tetrazolium salt that produced a
highly water-soluble formazan dye (Cell Counting Kit; Dojindo Labo- 
ratories Ltd., Japan) [18]. The absorbances of the aliquot supernatant 
of MIAPaCa-2 cells were measured to assay the cell growth at 450 nm 
using an automatic plate analyzer (Tokyo Sokki, Japan). Method B is 
as follows: the MIAPaCa-2 cells (5 x 105) were plated onto 4 cm 2 tissue 
culture wells in D-MEM containing 10% FBS. The cells cultured by the 
method described above were detached with 0.25% trypsin and 0.1% 
EDTA, and counted in triplicate by using a hemocytometer. 
2.3. Binding assay 
The MIAPaCa-2 cells were grown in 12-well plates. The confluent 
cells were washed with phosphate-buffered saline (PBS) and incubated 
with 1 ml of the binding medium (Hank's medium, pH 7.6, supple- 
mented with 0.1% bovine serum albumin) containing various concen- 
trations of ~25I-labelled mature hPLA2-I for 2 h at 4°C. After the cells 
were washed with PBS, the radioactivity bound to the cells was meas- 
ured. The specific binding was calculated from the differences between 
in the absence and the presence of unlabelled mature hPLA2-I (500 nM). 
2.4. Stat&tical analysis 
Statistical analysis was done using the Student's t-test. A probability 
of P < 0.05 was considered statistically significant. 
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Fig. 1. Dose effect of the mature hPLA2-I on the proliferation of 
MIAPaCa-2 cell line at the various concentrations. The data are repre- 
sentative of three experiments and each point and bar is the mean and 
the standard eviation, respectively. (A) the cell numbers counted by 
a hemocytometer; (B) the absorbances at450 nm measured by the Cell 
Counting Kit. D, 0 nM; A, 10 nM; o, 25 nM; e, 50 nM. *P < 0.05. 
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Fig. 2. Dose effects of pro and mature forms of hPLA2-I, and PLA2s 
from various ources on the proliferation of MIAPaCa-2 cell line. Each 
PLA2 was used at the final concentrations of 50 nM. The data are 
representative of three experiments and each column and bar is the 
mean and the standard eviation, respectively. *P < 0.05. 
3. Resu l ts  and d iscuss ion 
3.1. Purification of hPLA2-I from human pancreatic juice 
hPLA2-I is mainly secreted from the pancreas as an inactive 
zymogen and converted into the active form by trypsin. The 
mature form has been thought o function as a digestive nzyme 
[19]. In the present study, we purified to homogeneity the 14- 
kDa protein from the pancreatic juice by chromatography on 
Octyl-Sepharose and CM-Sepharose column. The Western- 
blot analysis confirmed that the 14-kDa protein is hPLA2-I. 
The N-terminal 20 amino acids sequence of the isolated hPLA2- 
I was identical with that of the mature hPLA2-I reported previ- 
ously [20]. 
3.2. Cell proliferation assay 
Through three experiments, we confirmed that the mature 
type of exogenous hPLA2-I, purified from pancreatic juice, 
stimulated the MIAPaCa-2 cell proliferation when added at the 
concentrations of 25 or 50 nM, respectively (P < 0.05) (Fig. 
1A,B) The dose of hPLA2-I at the high concentration of over 
100 nM, however, gave rise to reduction of the cell viability 
(data not shown). The treatment with the pro-form of hPLA2-I 
(50 nM) was ineffective to the cell proliferation of MIAPaCa-2. 
Other PLA2s (50 nM) from Laticauda semifasciata fraction I, 
Streptomyces violaceoruber, Crotalus adamanteus venom and 
bee venom did not stimulate the cell growth of MIAPaCa-2 
(Fig. 2). These results suggest hat the PLA2-induced MIA-  
PaCa-2 proliferation is specific for the mature form of hPLA2-I 
at the optimal dose concentration. 
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Fig. 3. Typical equilibrium binding assay of the mature hPLA2-I to 
MIAPaCa-2 cells. (A), saturation curves for the equilibrium binding of 
the mature hPLA2-I to MIAPaCa-2 cells. Specific binding (e) was 
calculated by subtracing the nonspecific binding (A) from the total 
binding (©). (B), Scatchard plot analysis on the specific ~25I-labelled 
hPLA2-1 binding data in (A). 
3.3. Binding assay 
We measured whether the mature 125I-labelled hPLA2-I is 
bound to the MIAPaCa-2 cell (Fig. 3A). The Scatchard plots 
demonstrated a single class of binding site for the mature 
hPLA2-I, with an equilibrium binding constant (Kd) value of 2.6 
nM and a maximum binding capacity (Bmax) of 0.4 fmol/106 cells 
(Fig. 3B). Although the Kd value to the MIAPaCa-2 cell was 
similar to that for the porcine PLAe-I bound to mouse embry- 
onic fibroblast (Swiss 3T3) cell [8] or rat embryonic thoracic 
aorta smooth muscle cell [21], the Bmax value in the present 
study was lower than that for the porcine PLA2-I for Swiss 3T3 
cells (8.34 fmol/106 cells), or rat embryonic thoracic aorta 
smooth muscle cells (35 fmol/106 cells) [8,21]. Judging from the 
Bmax value (0.4 fmol/106 cells), it may be reasonable that the 
higher dose (25, 50 nM) of hPLA2-I is necessary to stimulate 
the growth of MIAPaCa-2 cells. 
It has been reported that cancer cells may overexpress ome 
receptors which are activated by specific growth factors, lead- 
ing to excessive activation of growth signaling pathways and 
cell growth [22]. Human pancreatic carcinoma cells may over- 
express the receptors for epidermal growth factor (EGF) [23], 
or cholecystokinin (CCK) [24]. Cultured human pancreatic 
cancers overexpress EGF, transforming growth factor-alpha 
(TGF-~), and the receptors for EGF. The concept of a func- 
tional EGF autocrine cycle in human pancreatic arcinoma 
indicates that both EGF and TGF-~ may lead to excessive 
activation of the EGF receptor within the tumour [25]. Surpris- 
ingly, we demonstrated that a human pancreatic ancer cell 
line, MIAPaCa-2, had a single class binding site for the mature 
hPLA2-I, and that the mature hPLA2-I might function, not only 
as a digestive nzyme of pancreas, but also as a growth factor 
of pancreas carcinoma. Pancreatic neoplasms are usually duc- 
tal adenocarcinoma [25], and the ducts are encased and/or 
obstructed by the carcinoma. Previous studies have reported 
that some cases of pancreas carcinoma increase the PLA2 level 
in serum, because of pancreatitis a sociated with pancreas car- 
cinoma [26]. In addition, since the mature type of hPLA2-I has 
been found to be originally contained in the human pancreatic 
juice, together with the pro-form [27], a functional hPLA2-I 
paracrine loop might be present in human pancreas carcinoma. 
Further studies will be needed to investigate a functional 
hPLA2-I autocrine loop, and to understand the signal pathways 
for cell proliferation i  MIAPaCa-2. 
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